TABLE 3.
Adverse events
| Without AE n (%) |
G1 n (%) |
G2 n (%) |
G3 n (%) |
G4 n (%) |
|
|---|---|---|---|---|---|
| Hematopoietic toxicity | |||||
| leukopenia | 16 (84) | 2 (10.5) | 1 (5.3) | 0 | 0 |
| neutropenia | 17 (89.5) | 1 (5.3) | 1 (5.3) | 0 | 0 |
| lymphopenia | 13 (68.4) | 6 (31.6) | 0 | 0 | 0 |
| thrombocytopenia | 17 (89.5) | 2 (10.5) | 0 | 0 | 0 |
| anemia | 16 (84.2) | 3 (15.8) | 0 | 0 | 0 |
| febrile neutropenia | 0 | / | / | / | 0 |
| Non-hematopoietic toxicity | |||||
| arterial hypertension | 16 (84.2) | 2 (10.5) | 1 (5.3) | 0 | 0 |
| proteinuria | 12 (63.2) | 3 (15.8) | 3 (15.8) | 1 (5.2) | / |
| sepsis | 0 | / | / | / | 0 |
| diarrhea | 18 (94.7) | 1 (5.3) | 0 | 0 | 0 |
| vomiting | 17 (89.5) | 1 (5.3) | 1 (5.3) | 0 | 0 |
| muscle pain | 18 (84.7) | 1 (5.3) | 0 | / | / |
| intracranial hemorrhage | 0 | 0 | 0 | 0 | 0 |
| tromboembolic event | 0 | 0 | 0 | 0 | 0 |
0 = no adverse side effects; / = adverse events of this grade doesn’t exist